Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East

Core Viewpoint - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus to register and commercialize VIZZ for the treatment of presbyopia in the Middle East region, marking a significant expansion of its commercial partnerships outside the United States [1] Group 1: Agreement Details - The agreement allows Lunatus to retain exclusive commercialization rights for VIZZ in several Middle Eastern countries, including the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq [1] - LENZ Therapeutics will receive upfront, regulatory, and commercial milestone payments, along with a significant share of revenue generated in the region through a pre-determined minimum product supply price [1] Group 2: Product Information - VIZZ is the first and only FDA-approved aceclidine-based eye drop specifically for the treatment of presbyopia, highlighting its unique position in the market [1] - The commercial launch of VIZZ in the United States is gaining momentum, which supports the strategic expansion into international markets [1] Group 3: Company Strategy - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, demonstrating the company's commitment to expanding global access to this presbyopia therapy [1]